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Abstract
Type-2 diabetes is mediated by defects in either insulin secretion or insulin action. In an effort to identify extracts
that may stimulate glucose uptake, similar to insulin, a high throughput-screening assay for measuring glucose
uptake in skeletal muscle cells was established. During the screening studies to discover novel antidiabetic
compounds from microbial resources a Streptomyces strain PM0324667 (MTCC 5543, the Strain accession number at
Institute of Microbial Technology, Chandigarh, India), an isolate from arid soil was identified which expressed a
secondary metabolite that induced glucose uptake in L6 skeletal muscle cells. By employing bioactivity guided
fractionation techniques, a tri-substituted simple aromatic compound with anti-diabetic potential was isolated. It
was characterized based on MS and 2D NMR spectral data and identified as NFAT-133 which is a known
immunosuppressive agent that inhibits NFAT-dependent transcription in vitro. Our investigations revealed the
antidiabetic potential of NFAT-133. The compound induced glucose uptake in differentiated L6 myotubes with an
EC50 of 6.3 ± 1.8 μM without activating the peroxisome proliferator-activated receptor-g. Further, NFAT-133 was
also efficacious in vivo in diabetic animals and reduced systemic glucose levels. Thus it is a potential lead
compound which can be considered for development as a therapeutic for the treatment of type-2 diabetes. We
have reported herewith the isolation of the producer microbe, fermentation, purification, in vitro, and in vivo
antidiabetic activity of the compound.
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Background
In 2010, the global prevalence of diabetes was estimated
to have reached 285 million and it is predicted to reach
438 million in 2030. Available agents provide imperfect
control of the disease, and the medical need for better
therapies is widely recognized (Norman 2010). About
90% to 95% of patients have non-insulin dependent dia-
betes mellitus (NIDDM) or type-2 diabetes and the stan-
dard therapy for the treatment of NIDDM has its own
limitations (Mark 1997). Diet, oral hypoglycaemic drugs
and insulin are the standard modes of treatment.
However they are unable to achieve relief from diabetes.
This leads to acute and chronic complications. Hence
major efforts have been directed towards development
of oral hypoglycaemic drugs, to identify both novel insu-
lin secretagogues and compounds able to enhance insu-
lin action in target tissues.
High throughput screening of natural product libraries
had previously been attempted by us as an approach
towards identifying novel scaffolds with potent biological
activity (Kulkarni-Almeida et al. 2008). Several pharma-
ceutical industries use this approach to investigate nat-
ural product based library collections (Quinn et al.
2002). A major segment of these biota collections were
represented by microbial cultures. Among the microbial
resources actinomycetes have been proven to be a
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voglibose, valienamine, adiposin-1, and trestatin-B were
reported from Actinoplanes utahensis (Schmidit et al.
1977), Streptomyces hygroscopicus-limoneus (De Melo et
al. 2006; Kameda et al. 1980), S. calvus (Mahmud 2003;
Truscheit et al. 1981), and S. dimorphogenes (Yokose et
al. 1983; Yokose et al. 1984) respectively. Acarbose is an
oral alpha-glucosidase and alpha-amylase inhibitor that
was first launched by Bayer in Switzerland in 1989 for
the oral treatment of type-2 diabetes mellitus (Schmidit
et al. 1977). Voglibose is an alpha-glucosidase inhibitor
used for lowering post-prandial blood glucose levels in
people with diabetes mellitus. It is produced and mar-
k e t e di nI n d i ab yt r a d en a m eV o l i x
® and Vocarb
®(De
Melo et al. 2006). Valielamine, a precursor of voglibose
and a new aminocyclitol were isolated from the fermen-
tation broth of Streptomyces hygroscopicus subspecies
limoneus. It has more potent a-glucosidase inhibitory
activity against porcine intestinal sucrase, maltase and
isomaltase than valienamine, validamine and hydroxyl-
validamine which were reported as building blocks of
validamycins and microbial oligosaccharide a-glucosi-
dase inhibitors (Kameda et al. 1984; Xu et al. 2009).
One of the hallmarks of type-2 diabetes is decreased
sensitivity of cells to insulin. Our approach was to
explore microbial collections for extracts with anti-dia-
betic metabolites that stimulate glucose uptake in skele-
tal muscle cells. Using this strategy we have previously
identified plant extracts Aegle marmelos and Syzygium
cumini which stimulate glucose uptake activity in L6
myotubes. This activity was mediated by activation of
glucose uptake by glucose transporter 4 (GLUT4), per-
oxisome proliferator activator receptor gamma (PPAR-g)
and phosphatidylinositol 3’ kinase (PI3K), (Anandharajan
et al. 2006). Similarly, (Jung et al. (2006)) showed that
Ganoderma lucidum extract stimulates glucose uptake
activity in skeletal muscles by activating the regulatory
molecules PI3-kinase and AMP activated protein kinase
(AMPK). We explored the microbial metabolite extract
library in search of compounds that enhance glucose
uptake in skeletal muscle cells in presence of insulin.
Upon insulin treatment of skeletal muscles, the insulin
receptor is phosphorylated which activates a signal
transduction pathway leading to increased translocation
and GLUT4 (Yonemitsu et al. 2001). These features of
L6 myotubes are critical since GLUT4 is responsible for
insulin-dependent glucose uptake in the mature differ-
entiated skeletal muscle cell.
High throughput screening of diverse microbial meta-
bolite extract library was conducted for detecting glu-
cose uptake inducers in rat skeletal muscle cells. The
extract library is prepared from diverse microbes iso-
lated from variety of ecological units in India. 880
extracts representing Actinomycetes strains yielded eight
actives. These could stimulate glucose uptake in differ-
entiated skeletal muscle cells. The extract of an actino-
mycetes strain PM0324667 of the genera Streptomyces
showed reproducible glucose uptake activity through
several refermentation generations. Using fermented
broth of this strain, bioactivity guided fractionation was
conducted to isolate the active principle. We isolated
the compound NFAT-133, which was earlier, reported
as an immunosuppressive agent. This compound
induced significant glucose uptake in rat skeletal muscle
in presence of insulin. The activity was possibly
mediated through a PPAR-g independent mechanism.
Further, the compound showed a significant reduction
in plasma glucose and plasma insulin levels in diabetic
(db/db) mice as compared to vehicle treated animals. In
this paper, we report the antidiabetic activity of NFAT-
133 along with isolation of its producer microorganism,
identification, fermentation, and structure elucidation.
Materials and methods
Isolation of Streptomyces strain PM0324667
The Streptomyces strain PM0324667 was isolated from a
sandy soil sample collected from Jaipur in Rajasthan,
India. The soil was suspended in demineralised water
(10% w/v) and heated at 55°C for 6 minutes. 100 μlo f
the suspension was spread on CSPYME agar consisting
of casein (0.1%), corn starch (1.0%), K2HPO4, (0.05%),
peptone (0.1%), yeast extract (0.1%), malt extract (1.0%),
agar agar (1.5%), hydroxylamine (0.01%) and amphoteri-
cin-B (0.002%) with initial pH value of 7.0. The medium
plates were incubated at 30°C for seven days. The colo-
nies were transferred onto agarified ISP2 medium. ISP2
medium consisted of malt extract (1.0%), glucose (0.4%),
yeast extract (0.4%) and agar agar (1.6%) with initial pH
value of 7.0. The medium slants were incubated at 30°C
for 7 days. Typical colonies of streptomycetes, with
rough surface and chalky white or gray in color were
picked-up on ISP2 agar plates. 47 colonies were isolated
and purified from the arid soil sample. All 47 cultures
from arid soils were screened in the in vitro antidiabetic
assay. Streptomyces strain PM0324667 was one these 47
which showed consistent and reproducible antidiabetic
activity.
Taxonomy
Microscopic and macroscopic features of the strain
PM0324667 were examined by the classical microbiolo-
gical techniques. Total DNA sample of the strain was
prepared as reported (Arun et al. 2005). The 16S riboso-
mal RNA gene (16S rRNA) was amplified by polymerase
chain reaction (PCR) using genomic DNA and universal
primers 243F (5’-GGA TGA GCC CGC GGC CTA-3’)-
forward primer and 1385R (5’-CGG TGT GTA CAA
GGC CC-3’) - reverse primer and sequenced (Arun et
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sequences was performed using the BLAST algorithm
on the GenBank/EMBL/DDBJ/PDB.
Production of NFAT-133 by Streptomyces strain
PM0324667
Streptomyces strain PM0324667 (MTCC 5543) from the
ISP2 medium slant was inoculated into seed medium;
274-(1) consisting of glucose (1.5%), corn steep liquor
(0.5%), peptone (0.75%), yeast extract (0.75%), calcium
carbonate (0.2%) and sodium chloride (0.5%) with initial
pH value of 7.0. The culture was incubated on a rotary
shaker [240 revolutions per minute (rpm)] at 30°C (± 1°
C) for three days. 5 ml of this seed was inoculated into
100 ml fermentation medium; 5189M consisting of malt
extract (2.0%), yeast extract (0.2%), glucose (1.0%) and
(NH4)2HPO4, (0.005%) with initial pH value of 6.0. The
fermentation was carried out on a rotary shaker (240
rpm) at 30°C (± 1°C) for three days.
Extraction and isolation
The fermented broth was extracted with methanol (1:1,
v/v) and it was stirred for 60 minutes and filtered
through a coarse filter paper. The filtrate was concen-
trated using vacuum concentrator. The aqueous concen-
trate was passed through 10% (v/v) bed volume of
Diaion
® HP20 (SUPELCO) resin at the rate of 1 L/h.
The adsorbent on the resin was eluted with 80% metha-
nol after water wash. The methanolic extract was dis-
solved in demineralized water to get concentration of 75
mg/ml. 100 ml of this aqueous solution was partitioned
with 100 ml ethyl acetate (EA) five times. The EA
extracts were pooled together and dried on vacuum
concentrator.
The EA concentrate was dry charged to CombiFlash
chromatography instrument with pre packed Redisep
silica gel column (10 g). The column was sequentially
eluted with chloroform and methanol mixture (5-20%
methanol) and the fractions monitored by thin layer
chromatography (TLC). Similar fractions were pooled to
get three samples namely; Fraction-1, Fraction-2 and
Fraction-3. These samples along with crude extract of
EA were screened for glucose uptake activity. The active
Fraction-1 was subjected to reverse phase silica (C-18)
cartridge, strata™ from Phenomenex and eluted with
water: acetonitrile mixture in gradient mode. The pure
compound was recovered from the 20% acetonitrile elu-
ate, by evaporating acetonitrile and water using a high
vacuum concentrator.
Structure elucidation
HPLC was performed using a Lichrosphere RP-18 col-
umn (125 × 4 mm) in a Shimadzu LC-2010CHT Liquid
Chromatograph. The final purification was done on
Waters PrepLC 4000 System. Solvents used for reverse-
phase were of HPLC grade and normal-phase column
chromatography was performed with demineralized
commercial-grade solvents. Silica gel (SiO2; 200-300
mesh) was used for CC and GF254 (30-40 mm) TLC
plates were procured from Merck. An NMR spectrum
of the compound was recorded in CDCl3 on Bruker 300
MHz spectrometer with TMS as the internal standard.
Chemical shift δ values were expressed in ppm, and
coupling constant J in Hz. ESI LC-MS was recorded on
Bruker Daltonics. CombiFlash
® Sq 16× Teledyne Tech-
nologies Company ISCO attached with UV/VIS detector
was used for Flash chromatography, using RediSep
®
Flash Column silica 12 g Teledyne ISCO.
Large scale fermentation
A well-sporulated seven days old slant culture was
inoculated into 200 ml of seed medium consisting of
glucose (1.5%), corn steep liquor (0.5%), peptone
(0.75%), yeast extract (0.75%), calcium carbonate (0.2%),
and sodium chloride (0.5%) in demineralized water with
an initial pH value of 6.5-7.0 in 1 L erlenmeyer flasks.
All the flasks were incubated on a rotary shaker for 3
days at 230-250 rpm at 30°C (± 1°C). 2.5 L seed was
transferred to 150 L fermentor (B. Braun Melsungen
AG) containing 100 L production medium consisting of
malt extract (2.0%), yeast extract (2.0%), glucose (1.0%),
di-ammonium hydrogen phosphate (0.005%) in deminer-
alized water with initial pH value of 6.0 and fermented
with the following parameters: aeration 0.5 vvm, tem-
perature 30°C(± 1°C), agitation 100 rpm. 20% dextrose
solution was fed at 24 h of the fermentation cycle at 5%
(v/v) and the batch was harvested at 48 h. The whole
broth was extracted with equal volume of ethyl acetate
(EA). The EA extract was used for isolation of the com-
pound NFAT-133.
Determination of in vitro activity
Cell lines and Reagents
The cell lines, media and reagents used in the assay are
namely; alpha-MEM (Bioconcept), fetal bovine serum
(Gibco), penicillin-streptomycin solution (Sigma),
14C-2-
deoxyglucose (GE Healthcare, UK)), 2-deoxyglucose
( S i g m aA l d r i c h ,S t .L o u i s ,M O ,U S A ) ,K R P Hb u f f e r
(pH.7.4), Microscint PS (Perkin Elmer, USA), 96-well
plates (Nunc), L6 rat skeletal muscle cells (CRL1458,
ATCC, USA), human recombinant insulin (Sigma, St.
Louis, MO, USA), rosiglitazone (synthesized in house).
Assay Procedure
The metabolite extract library samples were screened for
the ability to induce glucose uptake in insulin stimulated
differentiated L6 myotubes. The L6 rat skeletal muscle
cells were seeded into 96 well cell culture plates in com-
plete medium (a-MEM + 10% fetal bovine serum + 1%
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carbon dioxide (CO2) atmosphere. After 48 h, the med-
ium was switched to a-MEM with 2% (v/v) fetal bovine
serum (FBS) in order to initiate differentiation. Media
change was ensured every 48 h. Compound treatment
was conducted once the myoblasts differentiated to
form myotubes. The differentiated and fused myotubes
were starved in serum free a-MEM for 4 h, treated with
samples and further incubated for 24 h. Following treat-
ment and incubation, the cells were sensitized with
insulin (200 nM) and incubated for 25 minutes. Radio-
active glucose pulsing was done at 0.06 μCi/ml for 10
minutes. The reaction was terminated with cold KRPH
buffer. The cell-associated radioactivity was determined
by lysing the cells with Microscint PS™ followed by
liquid scintillation counting (Huang et al. 2002). The
assay was performed in triplicate.
For all experiments, the L6 myoblasts obtained from
ATCC were used only up to passage seven and were uti-
lized within two months post revival of a new vial.
PPAR-g luciferase assay
PPAR-g activation is one of the key mechanisms
involved in glucose uptake. To determine if NFAT-133
was exerting its effects by activation of PPAR-g,al u c i -
ferase assay was performed using the expression vector
for human PPAR-g and the PPRE-tk-LUC reporter plas-
mid. CV1 cells were seeded onto 24 well plates and
transient transfections were conducted after over-night
incubation using lipofectamine (Invitrogen, CA, USA).
Five hours after transfection, the cells were treated with
each compound concentration for an additional 24 h,
and the luciferase assay (Promega) was performed
according to the manufacture’s protocol. Luminescence
was measured using the Safire2 reader. Transactivation
of human PPAR-g by 1 μM rosiglitazone is considered
as 100% activation and hence data for NFAT-133 is cal-
culated in comparison to rosiglitazone which was used
a sap o s i t i v ec o n t r o li nt h ea s s a y .T h ee n t i r ea s s a yw a s
performed in triplicates.
Determination of in vivo activity
Animals
Male db/db mice (7-9 weeks of age) were housed in
individually ventilated cages at room temperature of 22°
C ± 2°C, humidity at 55 ± 5%, with a 12:12-h light: dark
cycle and throughout the study period had access to
water and standard chow ad libitum. The guidelines of
the Committee for the Purpose of Control and Supervi-
sion of Experiments on Animals, Government of India,
were followed and the in-house animal ethics committee
approved all experimental procedures.
Biological Activity
Male db/db mice were divided into three groups of 10
animals each with similar body weight and plasma
glucose (mean ± S.E.M.) levels. Mice were treated
with 0.5% carboxy methyl cellulose (CMC), rosiglita-
zone (5 mg/kg, p.o.), or NFAT-133 (100 mg/kg, i.p.)
twice daily for 10 days. Body weight was measured
d a i l y .O nd a y1 0 ,o n eh o u ra f t e rt h el a s td o s e ,m i c e
were fasted for four hours so as to minimize the
variability between the animals. Blood was collected
from the fasted mice, plasma was separated by centri-
fugation (6000 g at 4°C for 7 minutes) and glucose
was estimated using a biochemistry auto analyzer
(Hitachi Science Systems Limited, Ibaraki, Japan). A
small aliquot of separated plasma was stored at -20°C
for estimation of insulin using an ELISA assay kit
(Linco Research). Immediately after blood sample col-
lection, mice were sacrificed, livers excised and
weighed. The data was reproducible in two indepen-
dent experiments.
Statistical analysis
All the results are expressed as Mean ± S.E.M. Statistical
analysis was done using GraphPad Prism 4 (version 4.03,
GraphPad Software, Inc., CA, USA). For comparison
between means of more than two groups one-way analy-
sis of variance (ANOVA) followed by Dunnett’sp o s t -
hoc analysis was employed.
Results
Taxonomy of the Streptomyces strain PM0324667
The morphological characteristics of the culture Strep-
tomyces strain PM0324667 on ISP2 agar were
observed. The colonies had a rough surface, marginal
areas divided into radial and concentric sections, dry,
burst substrate mycelia with profound aerial mycelia,
grayish sporulation, convoluted appearance, slightly
yellowish diffusible pigment diffusing into the medium
to give a buff yellow colour. The partial 16S rRNA
gene sequence of the Streptomyces strain PM0324667
has been deposited at NCBI and allocated accession #
JF810673. This strain showed high similarity in 16S
rRNA gene sequence value with Streptomyces pactum;
accession no. EF654095.1 (884/899, 98%). Moreover it
showed striking similarity (884/894, 98%) to Strepto-
myces parvisporogenes; accession numbers AB184375.1
and GU350508.1. The full phylogeny tree and blast
results are shown in Figure 1 We found that our cul-
ture isolate bears closer resemblance to S. parvisporo-
genes as the sequence JF810673 has 98% similarity with
the two sequences of S. parvisporogenes (Accession
numbers: AB184375.1 and GU350508.1). These pheno-
typic and genotypic properties suggest that the strain
PM0324667 belongs to the genus Streptomyces.T h e
strain is deposited and preserved at Institute of Micro-
bial Technology, Chandigarh, India (Council of Scienti-
fic and Industrial Research, CSIR) under accession
number Streptomyces sp. MTCC 5543.
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glucose uptake in differentiated skeletal muscle cells
Insulin resistance in skeletal muscle cells is known to
play a pivotal role in the development of diabetes. So we
established a high throughput screen using L6 differen-
tiated muscle cells as a model for evaluating the potency
of natural product extracts in inducing glucose uptake.
High throughput screening of the 20,000 microbial
extracts library was conducted. Among the actives the
extract from PM0324667 showed a 4-fold increase in
glucose uptake activity as compared to control. It
induced glucose uptake in differentiated L6 muscle cells
in presence of 25 mM glucose and 200 nM insulin. The
extract showed consistent and reproducible increase in
glucose uptake activity at 3 μg/ml (Figure 2: Where glu-
cose uptake in L6 myotubes exposed to vehicle (0.5%
DMSO), glucose uptake in presence of 30 μM rosiglita-
zone; glucose uptake in presence of 3 μg/ml of the
extract of PM034667) when subjected to several refer-
mentation cycles. This effect was comparable to the
effect of rosiglitazone at 30 μM (approximately equal to
10.75 μg/ml) in the same experiment.
Isolation and characterization of NFAT-133
As described in the experimental section, the EA
extract of the whole fermentation broth was subjected
to bioactivity-guided fractionation to identify the active
principle responsible for the glucose uptake activity in
PM034667. Three samples based on their fractional
similarity were evaluated in the biological assay viz.,
1111/38/1, 2 and 3. These samples along with the
crude 1111/27 were screened for glucose uptake activ-
ity in differentiated skeletal muscle cells. Since bioac-
tivity similar to that of rosiglitazone was observed to
b er e s i d i n gi nas i n g l ef r a c t i o n1 1 1 1 / 3 8 / 1 ,t h es a m e
fraction was taken up for further isolation of the active
principle (Table 1).
NFAT-133 was isolated by fermentation of the Strep-
tomyces culture PM0324667 using optimized fermenta-
tion media and conditions as described in the
experimental section. The biological activity coincided
with the profile on a LC-ESI positive ion mass spectrum
which showed a distinct peak m/z at 299 [M + Na]
+
suggesting a molecular weight of the compound was
276 (Additional file 1). The compound was a pale yellow
viscous oil with a UV absorption maxima of 212 nm,
and molecular formula; C17H24O3.
A
13C NMR spectra (Table 2, Additional file 2) indi-
cated eight carbons in the range of δ 128-140, these sig-
nals were characteristic of C = C system present in the
compounds. Another carbon signal at δ 214 indicated a
ketone unit in the structure. Two carbons at δ 63.8 and
74.6 were assigned as CH-OH and CH2-OH with the
help of HSQC (Additional file 3) and DEPT-135 spectra
(Additional file 4) of the compound NFAT-133.
The
1H NMR (Additional file 5) and COSY spectra
suggested the presence of trisubstituted benzene ring
with coupled proton signal at δ 7.2 (C-5), 7.07 (C-7) and
7.05 (C-8). A proton signal at δ2.3 singlets was assigned
as Me group at C-6 position. The olefinic protons at C-
Streptomyces sp.C203 16S ribosomal RNA gene, partial sequence
high GC Gram + l 8 leaves
high GC Gram + l 32 leaves
high GC Gram + l 16 leaves
high GC Gram + l 3 leaves
Uncultured bacterium clone A KIW955 16S ribosomal RNA gene, partial sequence
Streptomyces bingchengensis strain HBUM 174849 16S ribosomal RNA gene, partial sequence
high GC Gram + l 3 leaves
Streptomyces parvisporogenes strain MJM 12043 16S ribosomal RNA gene, partial sequence
Streptomyces catenulae strain HBUM 175064 16S ribosomal RNA gene, partial sequence
Streptomyces sp. 13651Q 16S ribosomal RNA gene,
high GC Gram + l 26 leaves
Streptomyces sp. P1400D 16S ribosomal RNA gene, partial sequence
Uncultured actinomycete clone MRS-7 16S ribosomal RNA gene, partial sequence
Streptomyces sp. 210726 16S ribosomal RNA gene, partial sequence
Streptomyces parvisporogenes gene for 16S rRNA, partial sequence, strain:NBRC 13394
Streptomyces pactum strain NRRL ISP-5530 16S ribosomal RNA gene, partial sequence
Streptomyces sp. PM0324667 16S ribosomal RNA gene, partial sequence
Streptomyces sp. PM0324667 16S ribosomal RNA gene, partial sequence
Figure 1 Phylogeny Tree view for query ID: JF810673, the partial 16S rRNA gene sequence from the of Streptomyces strain PM034667.
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lated in COSY spectrum.
The other proton signals were also assigned to their
respective carbons with the help of HSQC, COSY and
DEPT spectra of the compound. The complete interpre-
tation of data was in full agreement with the reported
values of the compound NFAT-133 (Figure 3) (Burres et
al. 1995; Qureshi et al. 2001).
Effect of NFAT-133 treatment in vitro
Bioactivity guided isolation of the active compounds
resulted in isolation of the compound NFAT-133. This
compound has been previously isolated from a Strepto-
myces strain AB 2184C-502 and derived its name
NFAT-133 due to its ability to inhibit the activation of
the transcription factor - NFAT in Jurkat T-cells and
block proliferation of splenocytes derived from Balb/c
and C57BL/6 mice in vitro (Burres et al.1995). Herewith
we report its effect on glucose uptake in differentiated
skeletal muscle cells. NFAT-133 induces increased glu-
cose uptake in L6 myotubes in presence of insulin (EC50
=6 . 3±1 . 8μM). This effect is comparable to the effect
of rosiglitazone (EC50 = 6.9 ± 1.8 μM) under similar
experimental conditions (Figure 4). However, unlike
rosiglitazone, NFAT-133 does not significantly affect
PPAR-g activity (Table 3). Rosiglitazone is a full agonist
of PPAR-g at 1 μM. Whereas NFAT-133 even at con-
centrations as high as 100 μM, does not induce PPAR-g
activity, indicating that NFAT-133 stimulates glucose
uptake via mechanisms distinct from that of
rosiglitazone.
Effect of NFAT-133 treatment in vivo
Rosiglitazone treatment induces glucose uptake in insu-
lin-resistant rat skeletal muscle cells by activating
PPAR-g and by increasing the resident AMPKa2 activity
of these cells. Similarly, troglitazone a PPAR-g dual ago-
nist increases glucose uptake by inducing GLUT4 trans-
location in L6 skeletal muscles (Lessard et al. 2006;
Yonemitsu et al. 2001). However, these compounds are
PPAR-g agonists, and have several side-effects that cause
increased body weight and hepaptoxicity on chronic
exposure. Since NFAT-133 increases glucose uptake in
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Figure 2 Effect of the ethyl acetate extract of Streptomyces strain PM034667 on glucose uptake in differentiated L6 myotubes
sensitized to insulin.
Table 1 Effect of the ethyl acetate extract (111/27/E.A) of
Streptomyces strain PM034667 and fractions 1111/38/1, 2
and 3 on glucose uptake in differentiated L6 myotubes
Sample # Glucose uptake in L6 myotubes*
(Fold increase over control at 3
μg/ml)
Inference
EA- crude 2.5 Active
Fraction-1 2.4 Active
Fraction-2 1.4 Not
active
Fraction-3 1.5 Not
active
Rosiglitazone (4 μg/
ml)
1.8 Active
*: n = 3
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significantly, we decided to investigate its in vivo profile
in diabetic animals. Prior to planning an efficacy study
we determined the pharmacokinetic profile of NFAT-
133 (Figure 5, Table 4) using female db/db mice with n
= 4 per time point. NFAT-133 was found to have poor
oral bioavailability. But, since the compound appeared
to have a novel mechanism of action, we decided to
explore its in vivo efficacy potential by attempting the
intraperitoneal route of administration. NFAT-133
administered by the intraperitoneal route achieved
plasma concentrations higher than the in vitro EC50 in
skeletal muscles. The dose selected, was 20 times higher
than that of rosiglitazone on the basis of the pharmaco-
kinetic profile of the compound, so as to have the suffi-
cient exposure to show the pharmacological effect.
NFAT-133 showed a significant reduction in plasma
glucose and plasma insulin levels as compared to
vehicle treated animals. The decrease in plasma glu-
cose and insulin in the NFAT-133 group was similar
to that observed in rosiglitazone treated group (Figure
6). The liver weight of rosiglitazone treated animals
was significantly increased as compared to vehicle
treated group, (Table 5) (2.3 ± 0.1 g vs. 2.7 ± 0.1 g),
while NFAT-133 had no effect on liver weight (2.0 ±
0.1 g). In addition, rosiglitazone showed significant
increase in body weight, which is the well known
adverse effect of PPAR-g agonists. Our compound
NFAT-133 showed significant reduction in body
weight gain as compared to the vehicle treated ani-
mals (% change in body wt: 6.02 ± 0.64, 14.63 ± 0.85
and -1.08 ± 1.21 in vehicle, rosiglitazone and NFAT-
133, respectively). This is a beneficial effect over the
compounds belonging to the class of PPAR-g agonists;
e.g., rosiglitazone (Table 5).
Discussion
Streptomyces pactum was known to produce antitumor
compounds like pactamycin (Bhuyan 1962), vasodilating
secondary metabolite like actinopyrones A, B and C
(Yano et al. 1986), NADH oxidase inhibitors such as
piericidin class of compounds (Matsumoto et al. 1987),
2+ 2
2+

 

 

Figure 3 Structure of NFAT-133.
Table 2 NMR assignment for NFAT-133 in CDCl3
Carbon#
13C NMR
1H NMR Reported
13C NMR Reported
1H NMR
1
63.8 (CH2
) 4.3, bs
63.7(CH2
) 4.2, dd
2 131.6 (CH) 6.2, dt 132.8(CH) 6.1, dt
3 128.9 (CH) 6.9, d 129.3(CH) 6.9 dt
4 136.1 (Q) – 137.2(Q) –
5 128.0 (CH) 7.2, Overlap 128.6(CH) 7.2, d
6 135.9 (Q) – 137.0(Q) –
7 128.7(CH) 7.07, dd 129.7(CH) 7.07 dd
8 126.6 (CH) 7.05, dd 128.0(CH) 7.05, d
9 138.6 (Q) – 140.2 (Q) –
10 37.3 (CH) 3.1, m 39.8(CH) 3.08, dq
11 74.6 (CH) 4.1, m 76.6(CH) 4.2, dd
12 48.5(CH) 2.5, m 51.2(CH) 2.3, qd
13 214 (Q) – 214.2 (Q) –
14
29.3 (CH3
) 2.1, s
28.4(CH3
) 2.05, s
15
21.1(CH3
) 2.3, s
21.0 (CH3
) 2.2, s
16
17.5(CH3
) 1.3, d
19.2(CH3
) 1.2, d
17
10.8(CH3
) 1.09, d
9.7(CH3
) 0.9, d
The NMR data for NFAT-133
1H NMR (500 MHz, CDCl3): δ 7.26 (1H, overlap, H-5), 7.07 (1H, d, H-7), 7.05 (1H, d, H-8), 6.9 (1H, d, J = 15.5 Hz, H-3), 6.2 (1H, dt, J = 15.5 Hz, H-2), 4.37 (2H, bs, H-1),
4.11 (1H, bs, H-11), 3.12 (1H, m, H-10), 2.52 (1H, m, H-12), 2.35 (3H, s, H-15), 2.14 (3H, s, H-14), 1.34 (3H, d, J = 7.0 Hz, H-16), 1.09 (3H, d, J = 7.0 Hz, H-17),
13C NMR (75 MHz, CDCl3): δ 214 (C = O), 138.6 (C, C-9), 136.13 (C, C-4), 135.9 (C, C-6), 131.6 (CH, C-2), 128.9 (CH, C-3), 128.74 (CH, C-7), 128.0 (CH, C-5), 126.6 (CH,
C-8), 74.65 (CH, C-11), 63.83 (CH2, C-1), 48.57 (CH, C-12), 37.3 (CH, C-10), 29.3 (CH3, C-14), 21.11 (CH3, C-15), 17.58 (CH3, C-16), 10.8 (CH3, C-17).
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al. 1989). Similarly Streptomyces parvisporogenes has
been reported to synthesize polyenic antifungal agent
like Antibiotic PA 616 (Chas 1960) and pepstatin class
of compounds which are pepsin inhibitors (Umezawa
1970). There has been no report of NFAT-133 or simi-
lar class of compounds isolated from strains of Strepto-
myces pactum or Streptomyces parvisporogenes to date.
Our screening program for new compounds has
yielded the compound NFAT-133. NFAT-133 elicits a
significant and dose dependent glucose uptake
response in differentiated L6 cells. In skeletal muscles
the glucose uptake is mediated by activation of the
transporter molecule GLUT4 (Wijesekara et al. 2006).
GLUT4 activation is controlled by regulatory proteins
which activate either the AMPK or PI3K pathway. Sev-
eral natural products have been earlier reported to eli-
cit similar responses in L6 skeletal muscle cells. We
have shown that the plant extracts Aegle marmelos and
Syzygium cumini stimulate glucose uptake in skeletal
muscle by augmenting the activity of the regulatory
molecules; phosphatidyl inositol-3-kinase (PI3K),
AMPK and GLUT-4 (Anandharajan et al. 2006). Gano-
derma lucidum extract stimulates glucose uptake in L6
rat skeletal muscle cells by stimulating the activity of
PI3K as well as a PI3K independent pathway which is
controlled by the AMP activated protein kinase (Kamei
et al. 2002; Jung et al. 2006; Cheng et al. 2006). It is
p o s s i b l et h a tN F A T - 1 3 3m a yb em e d i a t i n gi t se f f e c t s
through some of these pathways since the compound
did not significantly activate PPAR-g. PPAR-g is a
major signaling molecule that is implicated in glucose
uptake by skeletal muscle cells in vivo. However, acti-
vation of this receptor has several drawbacks. This has
been noted especially in the case of thiazolidinediones
which are very successful in reducing the clinical
symptoms of diabetes. However, their major drawback
is that they mediate their effects through activation of
the PPAR-g family of nuclear receptors. The most sig-
nificant side effects of this group of compounds
include weight gain, hepatotoxicity and cardiovascular
manifestations. The fact that our compound NFAT-
133 did not induce glucose uptake through activation
of PPAR-g is significant. Hence, we evaluated the effi-
cacy of the molecule in reducing systemic blood glu-
cose levels in db/db mice. Our data showed that
NFAT-133 reduces systemic blood glucose levels. This
was correlated with a simultaneous decrease in plasma
insulin. Though actinomycetes produce few but promi-
nent antidiabetic compounds, our report of NFAT-133
activity has revealed that further exploration of actino-
mycetes group will provide an avenue for discoveries
leading to new medicines for diabetes. In conclusion,
we found that NFAT-133, a natural product isolated
from Streptomycetes, stimulates glucose uptake in L6
myotubes. This mechanism might explain its antihy-
perglycemic effects in diabetic animals.
Table 3 Effect of NFAT-133 on PPAR-g activity in human
PPAR-g receptor transfected CV1 cells
Compound % hPPAR-g activation
NFAT-133, 100 μM* 9.0
NFAT-133, 30 μM* 0.2
Rosiglitazone, 1 μM* 100
*: n = 3
0.001 0.01 0.1 1 10 100
1.0
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2.0
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Figure 4 Dose dependent increase in glucose uptake activity in differentiated L6 mytubes sensitized with insulin and exposed to log
dose concentrations of NFAT-133 (-■-) and rosiglitazone (-▲-).
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Figure 5 Pharmacokinetic data of NFAT-133 by oral (A) and intraperitoneal (B) absorption in female db/db mice at 30 mg/kg.
Table 4 Pharmacokinetic (PK) profile of NFAT-133 (30 mg/kg) administered orally and intraperitoneally in female db/
db mice
PK Oral IP
T max (h) 0.08 0.08
C max (μg/ml) 3.41 11.653
C max (μM) 12.34 42.221
AUC last 0.63 3.217
AUC 0-infinity 0.65 3.553
T1/2 (h) 0.16 1.86
IP: intraperitoneal, Tmax (h): Time to maximum observed plasma concentration, Cmax: Maximum observed plasma concentration, AUClast: Area under the
concentration-time curve from time 0 to the time of last observed concentration, AUC0-infinity: Area under the concentration-time curve from time 0 to infinity,
and T1/2: Terminal half-life.
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Figure 6 Effect of NFAT-133 on plasma glucose and insulin in db/db mice. db/db mice were treated for 10 days, bis in die (b.i.d) with
vehicle, NFAT-133 [100 mg/kg, intra-peritoneal (i.p)] or rosiglitazone [5 mg/kg, per os (p.o.)]. Plasma glucose (A) and insulin (B) were measured
after 10 days of treatment. All the results are expressed as mean ± standard error of the mean (S.E.M). *** P value < 0.001 vs. vehicle group.
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Page 10 of 12Conclusions
Antihyperglycemic effects of the Streptomycetes com-
pound NFAT-133 has been revealed by in vitro and ani-
mal studies.
Additional material
Additional file 1: ESI-MS of the compound NFAT-133. The
chromatogram represents the molecular mass of the isolated compound
NFAT-133 from the Streptomyces strain PM0324667. The sample ID for
the compound was: 1111- 41-1.
Additional file 2:
13C NMR of the compound NFAT-133. The
chromatogram represents the
13C NMR of the isolated compound NFAT-
133 from the Streptomyces strain PM0324667. The sample ID for the
compound was: 1111-41-1.
Additional file 3:
13C HSQC of the compound NFAT-133. The
chromatogram represents the
13C HSQC of the isolated compound NFAT-
133 from the Streptomyces strain PM0324667. The sample ID for the
compound was: 1111-41-1.
Additional file 4: DEPT-135 of the compound NFAT-133. The
chromatogram represents the DEPT-135 of the isolated compound NFAT-
133 from the Streptomyces strain PM0324667. The sample ID for the
compound was: 1111-41-1.
Additional file 5:
1H NMR of the compound NFAT-133. The
chromatogram represents the
1H NMR of the isolated compound NFAT-
133 from the Streptomyces strain PM0324667. The sample ID for the
compound was: 1111-41-1.
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